Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Ovarian Cancer: Maintenance Following Frontline BevacizumabПодробнее

PARP + Maintenance Bevacizumab in Ovarian CancerПодробнее

Dr. Jason A. Konner on Bevacizumab in Advanced Ovarian CancerПодробнее

Bevacizumab in Recurrent Ovarian CancerПодробнее

Bevacizumab in Ovarian CancerПодробнее

Frontline Bevacizumab Strategies in Ovarian CancerПодробнее

When to Add Bevacizumab for Recurrent Ovarian CancerПодробнее

Dr. Dowdy on the Association of Molecular Subtypes and Responses to Bevacizumab in Ovarian CancerПодробнее

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancerПодробнее

Upfront Bevacizumab in Advanced Ovarian CancerПодробнее

Dr. Burger on the Use of Bevacizumab in Ovarian CancerПодробнее

Dr. Michael Birrer on Bevacizumab in Ovarian CancersПодробнее

Dr. Burger on Ovarian Cancer Maintenance Therapy With BevacizumabПодробнее

Dr. Dowdy on Bevacizumab and Improvement of PFS in Ovarian CancerПодробнее

Frontiers in Oncology - Evis Sala, MD, PhD, FRCRПодробнее

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian CancerПодробнее

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian CancerПодробнее

Maintenance Therapy: PARP Inhibitor or BevacizumabПодробнее

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancerПодробнее